Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-74699157 |
| Synonyms | |
| Therapy Description |
JNJ-74699157 binds to and inhibits GDP-bound KRAS G12C, resulting in decreased downstream signaling and potentially inhibiting tumor growth (PMID: 32014824). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-74699157 | JNJ 74699157|JNJ74699157|ARS3248|ARS 3248|ARS-3248 | KRAS G12C inhibitor 36 | JNJ-74699157 binds to and inhibits GDP-bound KRAS G12C, resulting in decreased downstream signaling and potentially inhibiting tumor growth (PMID: 32014824). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04006301 | Phase I | JNJ-74699157 | First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation | Completed | USA | FRA | 0 |